Table 5. Clinical relevance of M. kansasii respiratory isolates in previous reports.

Author, year, reference	Country	Study period	Clinical relevance*
Fogan, 1969 [34]	Oklahoma, USA	1966–1968	50% (18/36)
Jenkins, 1981 [9]	Wales, UK	1952–1978	84% (154/184)
O’Brien, 1987 [10]	USA	1981–1983	75% (762/1016)
Pang, 1991 [35]	Australia	1962–1987	48% (39/81)
Debrunner, 1992 [32]	Switzerland	1983–1988	26% (9/35)
Bloch, 1998 [11]	California, USA	1992–1996	88% (236/270)**
Corbett, 1999 [31]	South Africa	1996–1997	41% (23/56) †
Koh, 2006 [16]	South Korea	2002–2003	50% (7/14)
Bodle, 2008 [28]	New York City, USA	2000–2003	70% (7/10)
Van Ingen, 2009 [29]	Netherlands	1999–2005	71% (12/17)
Thomson, 2010 [36]	Australia	2005	53% (10/19)
Winthrop, 2010 [30]	Oregon, USA	2005–2006	38% (3/8)
Simons, 2011 [12]	Asia	1971–2007	17% (34/198)
Davies, 2012 [33]	UK	2000–2007	73% (40/55)
Braun, 2012 [25]	Israel	2004–2010	50% (7/14)
Jankovic, 2013 [26]	Croatia	2006–2010	50% (5/10)
Chien, 2014 [37]	Taiwan	2000–2012	44% (234/526)
Gommans, 2015 [27]	Netherlands	2001–2011	53% (10/19)
Current study	South Korea	2003–2014	52% (54/104)

USA = United States of America, UK = United Kingdom.

*Proportion of patients judged to have M. kansasii lung disease out of all patients from whom M. kansasii had been isolated.

**187 (69%) were HIV-positive.

^†40 (34%) were HIV-positive.